MANDARA -52wk,ph3 non-inferiority study comparing efficacy & safety of benralizumab & mepolizumab in EGPA receiv
Tweet Content
MANDARA -52wk,ph3 non-inferiority study comparing efficacy & safety of benralizumab & mepolizumab in EGPA receiving SOC
👉Benralizumab was non-inferior to mepolizumab in achieving remission at wks 36 & 48 (2.71%; 95% CI –12.54, 17.96; p=0.7278)
#ACR ABSTL14 @RheumNow #ACRbest https://t.co/S3aa3g5mnN
Show on Archive Page
On
Display in Search Results
On
PDQ
Off